Dr Nora Khaldi and Emmet Browne, NUritas

Nuritas appoints former Novartis global leader as chairman

Trade
Dr Nora Khaldi and Emmet Browne, NUritas

25 January 2016

Biotech start-up Nuritas has appointed former Novartis division head Dr George Gunn as chairman of the company’s board of directors.

Dr Gunn brings served as a member of the Novartis Global Executive Committee and Head of the Novartis Animal Health Division from 2004 until early 2015. He also served as division head for Novartis Consumer Health from 2008 to 2011 and was the head of corporate social responsibility for Novartis from 2011 to 2014.

Prior to Novartis, Dr Gunn practiced veterinary medicine for nine years before working at Johnson & Johnson and Pharmacia in an array of increasingly senior executive healthcare roles.

Emmet Browne, CEO of Nuritas, said: “As our opportunity is great so are the decisions that lie before us as we scale up. George’s depth of experience, knowledge and wisdom, gained at the highest levels of healthcare leadership, will be a huge addition to us as we deliver on the huge potential that lies within Nuritas.”

Nuritas also announced today that it had filled two other key positions on its advisory board in the areas of strategic translational science and food/product regulation.

Dr Dominique Bridon who has over 25 years of experience in therapeutic discovery, translational research and formulation. He is an expert in peptide development and commercialisation and has held roles had various roles such as head of research and development in multinational pharmaceutical companies as well as being a co-founder of a biotech start-up.

Steve Morrison brings over 20 years of regulatory experience in both the pharma and food areas. He is currently managing director of P2F (Pharma to Food) Ventures and was formerly CEO of Provexis.

Nuritas uses artificial intelligence to revolutionise therapeutics discovery by unlocking hidden properties in food ingredients.

TechCentral Reporters

Read More:


Back to Top ↑

TechCentral.ie